DrugPatentWatch Database Preview
Details for Patent: 8,795,725
Which drugs does patent 8,795,725 protect, and when does it expire?
Patent 8,795,725 protects HORIZANT and is included in one NDA.
This patent has twenty-three patent family members in sixteen countries.
Summary for Patent: 8,795,725
| Title: | GABA analog prodrug sustained release oral dosage forms |
| Abstract: | Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective. |
| Inventor(s): | Cundy; Kenneth C. (Redwood City, CA), Sastry; Srikonda (Sunnyvale, CA), Leung; Manshiu (Daily City, CA), Kadri; Balaji V. (Tampa, FL), Stach; Paul E. (Plymouth, MN) |
| Assignee: | XenoPort, Inc. (Santa Clara, CA) |
| Application Number: | 11/269,045 |
|
Patent Claim Types: see list of patent claims | Compound; Dosage form; Composition; Use; |
Drugs Protected by US Patent 8,795,725
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arbor Pharms Llc | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-002 | Dec 13, 2011 | RX | Yes | No | Start Trial | Start Trial | Y | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS | Start Trial | |||
| Arbor Pharms Llc | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-002 | Dec 13, 2011 | RX | Yes | No | Start Trial | Start Trial | Y | MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS | Start Trial | |||
| Arbor Pharms Llc | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-001 | Apr 6, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS | Start Trial | |||
| Arbor Pharms Llc | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-001 | Apr 6, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,795,725
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2005301970 | Start Trial | |||
| Brazil | PI0517227 | Start Trial | |||
| Canada | 2584338 | Start Trial | |||
| China | 101068538 | Start Trial | |||
| China | 102429882 | Start Trial | |||
| European Patent Office | 1811986 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
